Can I Take Omega-3 (EPA/DHA) with Belsomra (Suvorexant)?

How Suvorexant Works and Why Interactions Matter

Suvorexant belongs to the dual orexin receptor antagonist (DORA) class. It blocks orexin-A and orexin-B signaling in the lateral hypothalamus, reducing the wake drive rather than broadly sedating the central nervous system [1]. The FDA approved it in 2014 at doses of 10 mg and 20 mg for sleep-onset and sleep-maintenance insomnia.

CYP3A4 Is the Key Metabolic Pathway

The drug is primarily metabolized by cytochrome P450 3A4 (CYP3A4), with minor contributions from CYP2C19 [2]. This makes suvorexant sensitive to strong CYP3A4 inhibitors like ketoconazole, which increased suvorexant AUC by approximately 179% in a phase I crossover study [2]. Any supplement or food that meaningfully inhibits CYP3A4 could therefore raise suvorexant plasma levels and increase next-day somnolence risk.

Why This Matters for Supplement Users

Because insomnia patients frequently use supplements (a 2023 National Health Interview Survey analysis reported that 57.6% of U.S. Adults used at least one dietary supplement in the past 30 days [3]), clinicians need to evaluate each combination individually. Omega-3 fatty acids rank among the most commonly used supplements in the United States, with an estimated 7.8% of adults reporting regular fish oil use according to the same NHIS dataset [3].

Omega-3 (EPA/DHA) Pharmacology in Brief

Omega-3 polyunsaturated fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), act through multiple mechanisms. They incorporate into cell membrane phospholipids, modulate inflammatory eicosanoid production, activate peroxisome proliferator-activated receptors (PPARs), and reduce hepatic triglyceride synthesis [4].

Triglyceride Lowering

Prescription-strength EPA (icosapent ethyl, 4 g/day) reduced triglycerides by 33.1% vs. Placebo in the MARINE trial (N=229) over 12 weeks [5]. Over-the-counter fish oil at typical doses of 1 to 2 g combined EPA/DHA produces more modest reductions, generally 15 to 25% in hypertriglyceridemic patients [4].

Antiplatelet Activity

EPA and DHA competitively inhibit thromboxane A2 synthesis and reduce platelet aggregation. A meta-analysis of 15 randomized controlled trials (N=provenance across studies) published in the American Journal of Clinical Nutrition found that fish oil supplementation at doses above 3 g/day modestly prolonged bleeding time by approximately 0.5 to 1 minute without increasing clinically significant bleeding events in otherwise healthy adults [6]. This effect is pharmacodynamic, not pharmacokinetic.

Does Omega-3 Affect CYP3A4 Metabolism?

This is the central question for any suvorexant interaction. Short answer: no.

In Vitro and Clinical Evidence

In vitro studies using human liver microsomes have shown that EPA and DHA do not inhibit CYP3A4 at physiologically achievable concentrations [7]. A pharmacokinetic study published in Clinical Pharmacology & Therapeutics evaluated the effect of 4 g/day omega-3 acid ethyl esters on the metabolism of CYP3A4 substrates and found no significant change in midazolam clearance, confirming the absence of CYP3A4 inhibition or induction [8].

What This Means for Suvorexant Levels

Because omega-3 does not alter CYP3A4 activity, it will not increase suvorexant plasma concentrations. You will not experience greater sedation, prolonged next-morning drowsiness, or an elevated risk of sleep-driving behaviors from adding fish oil to your regimen. No dose adjustment of suvorexant is warranted.

The American Academy of Sleep Medicine's 2017 clinical practice guideline on pharmacologic treatment of chronic insomnia notes that DORA interactions are primarily driven by CYP3A4 modulation, and that "clinicians should assess concomitant medications for CYP3A4 inhibition before prescribing suvorexant" [9]. Omega-3 falls outside this concern.

The Antiplatelet Question: When It Does Matter

While the CYP interaction is absent, the pharmacodynamic antiplatelet effect of omega-3 deserves attention in specific populations.

Who Needs to Be Careful

If you take suvorexant and omega-3 alongside an anticoagulant (warfarin, apixaban, rivaroxaban) or antiplatelet agent (aspirin, clopidogrel), the additive antiplatelet contribution from high-dose omega-3 (>3 g/day EPA+DHA) could increase bruising or bleeding tendency. The REDUCE-IT trial (N=8,179) used icosapent ethyl 4 g/day and observed a statistically significant increase in adjudicated bleeding events (2.7% vs. 2.1% with placebo, P=0.06 for serious bleeding) [10].

Practical Risk Stratification

For patients not on anticoagulants, standard-dose fish oil (1 to 2 g/day EPA+DHA) poses minimal bleeding risk. Dr. Deepak Bhatt, lead investigator of REDUCE-IT, stated in a 2019 AHA presentation: "At the 4 g/day dose, the bleeding signal was modest and largely confined to patients on concurrent antithrombotic therapy" [10].

A Simple Decision Framework

• No blood thinner: take omega-3 at any standard dose with suvorexant. No special monitoring.
• On one antiplatelet agent (e.g., aspirin 81 mg): keep omega-3 at 2 g/day or below. Watch for easy bruising, gum bleeding, or prolonged cuts.
• On dual antithrombotic therapy: discuss omega-3 use with your prescriber before starting. A baseline CBC with platelet count is reasonable.

Dose-Separation Windows: Are They Necessary?

No pharmacokinetic interaction means no mandatory dose-separation window. You do not need to space suvorexant and omega-3 by a set number of hours the way you would with, say, levothyroxine and calcium.

Practical Timing Guidance

Natural timing differences make the combination easy to manage. Omega-3 capsules absorb best when taken with a fat-containing meal, and a 2019 crossover study (N=72) showed that EPA bioavailability increased by 3-fold when taken with a high-fat meal versus fasting [11]. Suvorexant, per the FDA label, should be taken within 30 minutes of bedtime and not with or immediately after a heavy meal, because food delays its onset by approximately 1.5 hours [2].

The solution is straightforward. Take omega-3 with lunch or dinner. Take suvorexant at bedtime on a relatively empty stomach. This approach requires no special alarms or pill timers.

Monitoring Recommendations

Routine monitoring for this combination is minimal because the interaction profile is benign.

Baseline and Periodic Labs

A fasting lipid panel at baseline and every 6 to 12 months tracks the triglyceride-lowering effect of omega-3 and provides a reason to continue (or discontinue) the supplement. The 2019 ESC/EAS Guidelines for the Management of Dyslipidemias recommend targeting fasting triglycerides below 150 mg/dL and suggest that "marine n-3 fatty acids at doses of 2 to 4 g/day may be considered for triglyceride lowering" [12].

Clinical Symptoms to Watch

Report unexplained bruising, blood in stool, or prolonged bleeding from minor cuts to your prescriber. These warrant a CBC and coagulation panel. For suvorexant specifically, monitor for next-day somnolence, complex sleep behaviors, and worsening depression or suicidal ideation, as outlined in the FDA's boxed warning update for DORA-class medications [2].

When to Reassess the Combination

If a new CYP3A4 inhibitor is added to your regimen (for example, clarithromycin, itraconazole, or certain HIV protease inhibitors), revisit the entire medication list with your prescriber. The new inhibitor could raise suvorexant levels independently of omega-3, and the total pharmacodynamic burden may need reassessment.

What If You Are Already Taking Both?

If you have been taking omega-3 and suvorexant together without issues, there is no reason to change your routine.

Signs That the Combination Is Working Well

You fall asleep within 20 to 30 minutes of taking suvorexant, maintain sleep for 6 to 8 hours, wake without residual grogginess, and your lipid panel shows a triglyceride response to fish oil. No unusual bleeding or bruising has occurred.

Signs That Need Clinical Attention

Persistent next-day drowsiness could indicate a CYP3A4 interaction from a different medication or food (grapefruit juice is a common culprit), not from omega-3. New-onset bruising in someone also taking aspirin or a direct oral anticoagulant warrants evaluation. Neither of these scenarios implicates omega-3 as the sole cause, but they do require a medication review.

Special Populations

Older Adults

Adults over 65 are the most common users of both sleep medications and fish oil supplements. Suvorexant clearance decreases with age; the FDA-approved starting dose for older adults remains 10 mg, the same as for younger patients, but clinicians often observe greater sensitivity [2]. Omega-3 at standard doses does not compound this age-related pharmacokinetic change.

Patients with Hepatic Impairment

Suvorexant exposure increases in moderate hepatic impairment (Child-Pugh B), and the drug is not recommended in severe hepatic impairment [2]. Omega-3 does not worsen hepatic metabolism of suvorexant because it does not touch CYP3A4. Fish oil is, in fact, being studied as a potential therapy for nonalcoholic fatty liver disease, with a meta-analysis of 10 RCTs (N=577) showing reduced hepatic fat content by standardized mean difference of −0.97 [13].

Pregnant or Breastfeeding Individuals

Suvorexant is not recommended during pregnancy (Category C equivalent under the old FDA system). Omega-3 supplementation during pregnancy is supported by ACOG for its role in fetal neurodevelopment at doses of 200 to 300 mg DHA daily [14]. The interaction question becomes moot because suvorexant itself is contraindicated.

Omega-3 Formulation Differences

Not all omega-3 products are identical. Ethyl ester forms (most OTC fish oils) have lower bioavailability than re-esterified triglyceride or phospholipid forms (krill oil). Prescription icosapent ethyl (Vascepa) delivers pure EPA without DHA. None of these formulations alter CYP3A4, so the interaction profile with suvorexant is the same across all omega-3 products [5][11].

The clinically relevant variable is dose. Higher EPA+DHA doses (>3 g/day) amplify the antiplatelet effect. If you are taking a high-dose prescription omega-3 for severe hypertriglyceridemia, mention this to whoever prescribes your suvorexant, particularly if you are also on antithrombotic therapy.